Clinical Trial Update: Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pimavanserin as an adjunctive treatment for the negative symptoms of schizophrenia has completed; results on efficacy and safety have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-04-01